|Bid||39.58 x 0|
|Ask||39.58 x 0|
|Day's Range||38.13 - 40.36|
|52 Week Range||20.36 - 76.68|
|Beta (3Y Monthly)||2.42|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.83|
On December 19 at 8:40 AM EST, Tilray (TLRY) was trading with a gain of nearly 4.6% at ~$80. The stock kept climbing after it gained 16% in the December 18 trading session.
The seventh development that we’ll be closely watching in the cannabis sector in 2019 will be the developments in the US. Now that hemp legalization has occurred, it will be interesting to see how the cannabis sector shapes up through the window of hemp products. Without the political will, no regulations around the cannabis sector (MJ) can become a reality.
Canopy Rivers Inc. (the “Company” or “Canopy Rivers”) (RIV.V) is pleased to announce that its shares have received DTC full service eligibility in the United States. The Company’s identifier is “CNPOF”.
One of Wall Street's most notorious short-sellers — and a onetime skeptic of marijuana stocks — is giving Canadian cannabis producer Aphria a big assist.
Will marijuana stocks implode in 2019? Will the farm bill be a major catalyst? Here's a 2019 outlook for what to expect from the marijuana industry.
Aphria (APHA)(APHQF) surged almost 9% today as of 2:10 PM ET. The stock gained momentum as a result of a press release announcing that the company will introduce its oral strip to the German market. This product is to work in conjunction with a previously announced agreement with Rapid Dose for the exclusive right to manufacture, license, and distribute Rapid Dose’s QuickStrip oral strip.The details
OTCQX: TRSSF), NETA NJ LLC (“NETA”), has been selected by the State of New Jersey Department of Health to apply for final approval to operate a vertically integrated Alternative Treatment Center (ATC), which would permit it to cultivate, process and sell medical cannabis in the state. The State of New Jersey received a total of 146 applications to cultivate, process and sell medical cannabis.
Earlier on December 18, Tilray (TLRY) announced a supply deal with Novartis—one of the largest global drug makers. Tilray stock rose nearly 11% following the announcement. Novartis stock was trading ~1.3% lower on in the European market.
The cannabis industry will likely continue to move beyond early-stage products such as dried cannabis flower to more value-added products with a variety of uses and formats of consumption. Companies (HMMJ) such as Canopy Growth (WEED), Cronos Group (CRON), Organigram (OGRMF), and CannTrust (CNTTF) may move to differentiate their products including extracts, gels, oils, and other formats to carve out their niche in the highly competitive market. The next development that we’ll be closely watching in 2019 is consolidation and synergies. We’ll be interested in seeing how the cannabis market continues to consolidate with more acquisitions. We’ll also be watching the evolution of partnerships and ventures between cannabis companies with the goal of taking advantage of synergies.
Should Ontario's latest news impact your decision to own Canopy Growth (TSX:WEED) (NYSE:CGC) or its pot stock peers.
Embedded within the recently passed $867 billion 2018 Farm Bill, was a provision for industrial hemp ...
2019 will likely be the busiest year yet for the cannabis sector (MJ), and it will also be the year when the cannabis sector sees its first full year of realized potential after legalization in Canada. Will the cannabis industry validate the premises behind its existence such as huge market demand, reduced crime, and access to better quality of products for adult use? In the quarterly earnings, we’ll see how companies performed year-over-year with regards to their revenue growth and profitability.
The cannabis industry has seen highs and lows in 2018. Before we do that, let’s recap what happened to the four developments listed in our previous series from June, Top Four Developments We’re Watching in the Cannabis Sector. In the second half of 2018, the cannabis sector remained busy getting cannabis products from production to customers.
In the earlier part of this series, we looked at how Canopy Growth (WEED) is testing hemp-based CBD products to lower anxiety in dogs. While talking about the different uses of hemp-based CBD in its Q2 2019 earnings call, Canopy Growth said that it could develop anti-inflammatory products such as sports drinks for the US market. Canopy Growth is preparing for the US market, but Tilray (TLRY) is not far behind.
With the demand for hemp growing by leaps and bounds, could it be time to take another look at pot stocks like Canopy Growth Corp (TSX:WEED)(NYSE:CGC)?
Canopy Growth is expected to spend nearly 5.3 million Canadian dollars in research and development in 2019, as seen in the above chart. Canopy Growth stated that it is developing CBD-based drugs to lower anxiety in dogs. The company believes that this development could then lead it to develop an anxiety-reducing drug for geriatric patients. For Canopy Growth, it is more important to find end uses of CBD products from hemp than to pursue the farming and extraction business.
The latest developments in the US, particularly the ones surrounding the Farm Bill, have been encouraging to the cannabis industry in the US. One of the most important changes that cannabis companies have been waiting for is legislation on hemp farming. On December 12, the Senate passed the Farm Bill, which will have a term of five years. The bill makes hemp a legal agricultural commodity, which would allow cannabis companies a legal foray into the US cannabis market.
Not only has it caused a stir with US pot stocks but Canadian marijuana stocks are also seeing more activity this week. With marijuana stocks in focus, here are 4 pot stocks to watch this month. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced earlier this month that as a part of its growth strategy to cover the major verticals associated with primary care, it has signed a binding Letter of Intent to acquire a Vancouver, British Columbia based pharmacy.
In the week ending December 14, the cannabis sector was broadly in the negative territory. The Horizons Marijuana Life Sciences ETF (HMMJ) fell 6.1% week-over-week. The ETFMG Alternative Harvest ETF (MJ) also ended in the negative territory with a 5.7% decline, while the Emerging Marijuana Growers Index ETF (HMJR) declined 2.5% during the same period.
When the going gets tough in the Canadian marijuana market, there could be a surprising winner.